New canine clinical research evaluates reversal of age-related signs in dogs

Positive results seen in old dogs in placebo-controlled trial performed at leading vet school, Animal Bioscience announces.

Pet longevity company Animal Bioscience today announced new clinical research published to the preprint server BioRxiv that tested the efficacy of their ‘LeapYears‘ supplement designed to extend lifespan in dogs.

Longevity.Technology: After five years of development and testing in dogs, leveraging discoveries made at Harvard Medical School, Animal Bioscience’s placebo-controlled study yielded positive results, and although the findings are not yet peer reviewed, the data is set to make LeapYears the first ever animal product clinically proven to reverse age-related decline in dogs.

It’s an exciting time for pet longevity; Animal Bioscience’s clinical trial has positive results and the results of Arterra‘s clinical study should be released in a couple of months. When you add Loyal into the mix – its clinical trial for a drug designed to extend the healthy lifespan of senior dogs kicked off earlier this month, and it has has received what it believes to be the FDA’s “first-ever formal acceptance that a drug can be developed and approved to extend lifespan” – and the pet longevity space looking positively bright-eyed and bushy-tailed. It would seem that 2024 is a leap year in more ways than one. 

New canine clinical research evaluates reversal of age-related signs in dogs

The LeapYears supplement, which formulated as a soft chew, is a combination of an NAD booster and a senolytic to clear out the senescent cells that contribute to aging. The proprietary formula is patented, but given it is listed as “formulations of nicotinic acid derivatives and flavonoid polyphenols”, we would speculate that nicotinamide riboside and/or nicotinamide mononucleotide might be in the potential line-up, along with usual senolytic suspects, quercetin, fisetin and apigenin.

Animal Bioscience says the combination of NAD booster plus senolytic was developed because the effects in vivo were better than the single molecules alone. The double-blind clinical study, which was conducted at North Carolina State University Veterinary College, a leading vet school, in collaboration with Dr Natasha Olby, a Professor of Neurology and Neurosurgery, has confirmed one of the effects of the supplement is a significant improvement in cognitive function [1]. The company adds that the formulation may have broader effects on frailty, activity and happiness, as assessed by owners.

“The outcomes of the clinical trial, especially the enhancements in cognition, are encouraging and represent a unique achievement,” Olby said. “This rigorous study, which acknowledges the difficulties aging pets and their owners encounter, shows dedication to scientific methods aimed at improving the quality of life for our canine companions.”

New canine clinical research evaluates reversal of age-related signs in dogs
Nick Sinclair (L) is CEO of LeapYears, and Dr Ginny Rentko is CVMO

In senior dogs, as in humans, age-related decline can manifest as cognitive decline, increased frailty and poor quality of life. Animal Bioscience says this trial has shown other positive impacts in areas of decline, such as vitality, sleep, and engagement.

Dr David A Sinclair, AO, PhD, Professor of Genetics at Harvard Medical School and co-founder of Animal Bioscience said: “I am very proud of the teams at NCSU and Animal Bioscience, who, after years of collaborative research and clinical trials, have developed the first supplement proven to reverse the effects of aging in dogs.”


Photographs courtesy of Animal Bioscience